Deepak Cyril Dsouza, MBBS, MD

• Angus Nairn
• Christopher Gottschalk
• Christopher van Dyck
• David Matuskey
• Edward Perry
• Elizabeth Ralevski
• Gerard Sanacora
• Graeme Mason
• Ilan Harpaz-Rotem
• Irina Esterlis
• Ismene Petrakis
• Joao P. De Aquino
• John Cahill
• John Krystal
• Joseph Lucien Goulet
• Keith Hawkins
• Kelly Cosgrove
• Kyung-Heup Ahn
• Marina Picciotto
• Michael Bloch
• Nabeel Nabulsi
• Peter Morgan
• Ralitza Gueorguieva
• Richard Carson
• Robert Pietrzak
• Samuel Wilkinson
• Scott Woods
• Sherry McKee
• TuKiet Lam
• Vinod Srihari

Behavior and Behavior Mechanisms; Mental Disorders; Behavioral Disciplines and Activities; Psychological Phenomena; Psychiatry and Psychology

• Dysregulation of the endogenous cannabinoid system following opioid exposureMohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.
• Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptomsSkosnik P, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal Of Psychopharmacology 2023, 37: 687-697. PMID: 37392016, DOI: 10.1177/02698811231179800.
• The Acute Effects of Cannabinoids in Patients with Psychotic IllnessGanesh S, Henquet C, Sewell R, Kuepper R, Ranganathan M, D’Souza D. The Acute Effects of Cannabinoids in Patients with Psychotic Illness. 2023, 225-239. DOI: 10.1017/9781108943246.023.
• Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information ProcessingMartin A, Ranganathan M, D’Souza D. Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing. 2023, 156-166. DOI: 10.1017/9781108943246.017.
• Cannabis, cannabinoids and psychosis: a balanced viewD'Souza D. Cannabis, cannabinoids and psychosis: a balanced view. World Psychiatry 2023, 22: 231-232. PMID: 37159370, PMCID: PMC10168157, DOI: 10.1002/wps.21075.
• Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophreniaSurti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.
• Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesiclesGanesh S, Lam T, Garcia-Milian R, D'Souza D, Nairn A, Elgert K, Eitan E, Ranganathan M. Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles. The World Journal Of Biological Psychiatry 2023, 24: 603-613. PMID: 36994633, PMCID: PMC10471733, DOI: 10.1080/15622975.2023.2197039.
• Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responsesSchnakenberg Martin A, Flynn L, Sefik E, Luddy C, Cortes-Briones J, Skosnik P, Pittman B, Ranganathan M, D’Souza D. Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses. Psychopharmacology 2023, 240: 1235-1246. PMID: 37045988, DOI: 10.1007/s00213-023-06356-0.
• Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trialSloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.
• Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis UsersJohnson E, Colbert S, Jeffries P, Tillman R, Bigdeli T, Karcher N, Chan G, Kuperman S, Meyers J, Nurnberger J, Plawecki M, Degenhardt L, Martin N, Kamarajan C, Schuckit M, Murray R, Dick D, Edenberg H, D’Souza D, Di Forti M, Porjesz B, Nelson E, Agrawal A. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. Schizophrenia Bulletin 2022, 49: 778-787. PMID: 36545904, PMCID: PMC10154717, DOI: 10.1093/schbul/sbac196.
• The therapeutic potential of psychedelicsSchindler E, D'Souza D. The therapeutic potential of psychedelics. Science 2022, 378: 1051-1053. PMID: 36480624, DOI: 10.1126/science.abn5486.
• Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trialSchindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.
• Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PETRadhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PET. NeuroImage 2022, 264: 119674. PMID: 36243269, DOI: 10.1016/j.neuroimage.2022.119674.
• Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression Among Adults in the US Veterans Affairs Health Care SystemBigdeli TB, Voloudakis G, Barr PB, Gorman BR, Genovese G, Peterson RE, Burstein DE, Velicu VI, Li Y, Gupta R, Mattheisen M, Tomasi S, Rajeevan N, Sayward F, Radhakrishnan K, Natarajan S, Malhotra AK, Shi Y, Zhao H, Kosten TR, Concato J, O’Leary T, Przygodzki R, Gleason T, Pyarajan S, Brophy M, Huang GD, Muralidhar S, Gaziano JM, Aslan M, Fanous AH, Harvey PD, Roussos P, Aslan M, Antonelli M, de Asis M, Bauer M, Brophy M, Concato J, Cunningham F, Freedman R, Gaziano M, Gleason T, Harvey P, Huang G, Kelsoe J, Kosten T, Lehner T, Lohr J, Marder S, Miller P, O Leary T, Patterson T, Peduzzi P, Przygodski R, Siever L, Sklar P, Strakowski S, Zhao H, Fanous A, Farwell W, Malhorta A, Mane S, Palacios P, Bigdeli T, Corsey M, Zaluda L, Johnson J, Sueiro M, Cavaliere D, Jeanpaul V, Maffucci A, Mancini L, Deen J, Muldoon G, Whitbourne S, Canive J, Adamson L, Calais L, Fuldauer G, Kushner R, Toney G, Lackey M, Mank A, Mahdavi N, Villarreal G, Muly E, Amin F, Dent M, Wold J, Fischer B, Elliott A, Felix C, Gill G, Parker P, Logan C, McAlpine J, DeLisi L, Reece S, Hammer M, Agbor-Tabie D, Goodson W, Aslam M, Grainger M, Richtand N, Rybalsky A, Al Jurdi R, Boeckman E, Natividad T, Smith D, Stewart M, Torres S, Zhao Z, Mayeda A, Green A, Hofstetter J, Ngombu S, Scott M, Strasburger A, Sumner J, Paschall G, Mucciarelli J, Owen R, Theus S, Tompkins D, Potkin S, Reist C, Novin M, Khalaghizadeh S, Douyon R, Kumar N, Martinez B, Sponheim S, Bender T, Lucas H, Lyon A, Marggraf M, Sorensen L, Surerus C, Sison C, Amato J, Johnson D, Pagan-Howard N, Adler L, Alerpin S, Leon T, Mattocks K, Araeva N, Sullivan J, Suppes T, Bratcher K, Drag L, Fischer E, Fujitani L, Gill S, Grimm D, Hoblyn J, Nguyen T, Nikolaev E, Shere L, Relova R, Vicencio A, Yip M, Hurford I, Acheampong S, Carfagno G, Haas G, Appelt C, Brown E, Chakraborty B, Kelly E, Klima G, Steinhauer S, Hurley R, Belle R, Eknoyan D, Johnson K, Lamotte J, Granholm E, Bradshaw K, Holden J, Jones R, Le T, Molina I, Peyton M, Ruiz I, Sally L, Tapp A, Devroy S, Jain V, Kilzieh N, Maus L, Miller K, Pope H, Wood A, Meyer E, Givens P, Hicks P, Justice S, McNair K, Pena J, Tharp D, Davis L, Ban M, Cheatum L, Darr P, Grayson W, Munford J, Whitfield B, Wilson E, Melnikoff S, Schwartz B, Tureson M, D Souza D, Forselius K, Ranganathan M, Rispoli L, Sather M, Colling C, Haakenson C, Kruegar D, Muralidhar S, Ramoni R, Breeling J, Chang K, O Donnell C, Tsao P, Moser J, Brewer J, Warren S, Argyres D, Stevens B, Humphries D, Do N, Shayan S, Nguyen X, Pyarajan S, Cho K, Hauser E, Sun Y, Wilson P, McArdle R, Dellitalia L, Harley J, Whittle J. Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression Among Adults in the US Veterans Affairs Health Care System. JAMA Psychiatry 2022, 79: 1092-1101. PMID: 36103194, PMCID: PMC9475441, DOI: 10.1001/jamapsychiatry.2022.2742.
• Illness Phase as a Key Assessment and Intervention Window for PsychosisKohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.
• Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorderD’Souza D, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022, 47: 1854-1862. PMID: 35660802, PMCID: PMC9372173, DOI: 10.1038/s41386-022-01344-y.
• Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trialAbdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, Purohit P, Brundige A, Murff W, Ahn KH, Sherif MA, Baltutis EJ, Ranganathan M, D’Souza D, Martini B, Southwick SM, Petrakis IL, Burson RR, Guthmiller KB, López-Roca AL, Lautenschlager KA, McCallin JP, Hoch MB, Timchenko A, Souza SE, Bryant CE, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH. Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 2022, 47: 1583-1584. PMID: 35545665, PMCID: PMC9205895, DOI: 10.1038/s41386-022-01339-9.
• Sex Differences in the Acute Effects of Intravenous (IV) Delta-9 Tetrahydrocannabinol (THC)Nia A, Orejarena M, D’Souza D, Skosnik P, Pittman B, Ranganathan M. Sex Differences in the Acute Effects of Intravenous (IV) Delta-9 Tetrahydrocannabinol (THC). Biological Psychiatry 2022, 91: s69. DOI: 10.1016/j.biopsych.2022.02.191.
• Psychedelics: Old trips, new destinations in psychopharmacology researchde Wit H, D’Souza D. Psychedelics: Old trips, new destinations in psychopharmacology research. Psychopharmacology 2022, 239: 1643-1645. DOI: 10.1007/s00213-022-06152-2.
• Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)Bassir Nia A, Orejarena MJ, Flynn L, Luddy C, D’Souza D, Skosnik PD, Pittman B, Ranganathan M. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). Psychopharmacology 2022, 239: 1621-1628. PMID: 35438304, DOI: 10.1007/s00213-022-06135-3.
• Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosisD’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.
• EditorialD’Souza D, Curran HV. Editorial. Psychopharmacology 2022, 239: 1143-1145. PMID: 35316359, DOI: 10.1007/s00213-022-06110-y.
• Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trialAbdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, Purohit P, Brundige A, Murff W, Ahn KH, Sherif MA, Baltutis EJ, Ranganathan M, D’Souza D, Martini B, Southwick SM, Petrakis IL, Burson RR, Guthmiller KB, López-Roca AL, Lautenschlager KA, McCallin JP, Hoch MB, Timchenko A, Souza SE, Bryant CE, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 2022, 47: 1574-1581. PMID: 35046508, PMCID: PMC8767037, DOI: 10.1038/s41386-022-01266-9.
• TU85. POLYGENIC RISK SCORE FOR CANNABIS USE DISORDER PREDICTS ACUTE INTOXICATING EFFECTS AND COGNITIVE DEFICITS INDUCED BY DELTA-9-TETRAHYDROCANNABINOL: A PILOT STUDYGanesh S, Levey D, Ranganathan M, Gelernter J, D'Souza D. TU85. POLYGENIC RISK SCORE FOR CANNABIS USE DISORDER PREDICTS ACUTE INTOXICATING EFFECTS AND COGNITIVE DEFICITS INDUCED BY DELTA-9-TETRAHYDROCANNABINOL: A PILOT STUDY. European Neuropsychopharmacology 2021, 51: e142. DOI: 10.1016/j.euroneuro.2021.08.086.
• Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Bassir Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.
• Differential Cognitive Performance in Females and Males with Regular Cannabis UseMartin A, D’Souza D, Newman SD, Hetrick WP, O’Donnell B. Differential Cognitive Performance in Females and Males with Regular Cannabis Use. Journal Of The International Neuropsychological Society 2021, 27: 570-580. PMID: 34261548, PMCID: PMC8830784, DOI: 10.1017/s1355617721000606.
• The effect of ketamine on psychopathology and implications for understanding schizophrenia and its therapeutic use: a meta-analysisBeck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, Driesen N, Ranganathan M, D'Souza D, Taylor M, Krystal J, Howes O. The effect of ketamine on psychopathology and implications for understanding schizophrenia and its therapeutic use: a meta-analysis. BJPsych Open 2021, 7: s237-s237. PMCID: PMC8771247, DOI: 10.1192/bjo.2021.634.
• In vivo evidence of lower synaptic vesicle density in schizophreniaRadhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.
• Association of Cannabis Use During Adolescence With NeurodevelopmentAlbaugh MD, Ottino-Gonzalez J, Sidwell A, Lepage C, Juliano A, Owens MM, Chaarani B, Spechler P, Fontaine N, Rioux P, Lewis L, Jeon S, Evans A, D’Souza D, Radhakrishnan R, Banaschewski T, Bokde ALW, Quinlan EB, Conrod P, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Ittermann B, Martinot JL, Martinot M, Nees F, Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H. Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA Psychiatry 2021, 78: 1031-1040. PMID: 34132750, PMCID: PMC8209561, DOI: 10.1001/jamapsychiatry.2021.1258.
• Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysisFang XT, Toyonaga T, Hillmer AT, Matuskey D, Holmes SE, Radhakrishnan R, Mecca AP, van Dyck CH, D’Souza D, Esterlis I, Worhunsky PD, Carson RE. Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. NeuroImage 2021, 237: 118167. PMID: 34000404, PMCID: PMC8452380, DOI: 10.1016/j.neuroimage.2021.118167.
• Differential Effects of Childhood Vs. Adulthood Trauma in Cannabinoid Receptor Type 1 (CB1R) Availability in Post-Traumatic Stress Disorder (PTSD): A Review of Literature and Pilot Positron Emission Tomography (PET) StudyNia A, D'Souza C, Cosgrove K, Pietrzak R, Harpaz-Rotem I. Differential Effects of Childhood Vs. Adulthood Trauma in Cannabinoid Receptor Type 1 (CB1R) Availability in Post-Traumatic Stress Disorder (PTSD): A Review of Literature and Pilot Positron Emission Tomography (PET) Study. Biological Psychiatry 2021, 89: s328-s329. DOI: 10.1016/j.biopsych.2021.02.820.
• Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophreniaRanganathan M, Rahman M, Ganesh S, D’Souza D, Skosnik PD, Radhakrishnan R, Pathania S, Mohanakumar T. Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. The World Journal Of Biological Psychiatry 2021, 23: 33-45. PMID: 33821753, DOI: 10.1080/15622975.2021.1907720.
• Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorderD’Souza D, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry 2020, 26: 3192-3200. PMID: 32973170, DOI: 10.1038/s41380-020-00891-4.
• A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressantsAbdallah CG, Ahn KH, Averill LA, Nemati S, Averill CL, Fouda S, Ranganathan M, Morgan PT, D’Souza D, Mathalon DH, Krystal JH, Driesen NR. A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology 2020, 46: 478-485. PMID: 32967000, PMCID: PMC7852889, DOI: 10.1038/s41386-020-00864-9.
• In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteersSchindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.
• Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory StudiesGanesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D’Souza D. Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. The International Journal Of Neuropsychopharmacology 2020, 23: 559-570. PMID: 32385508, PMCID: PMC7710917, DOI: 10.1093/ijnp/pyaa031.
• Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaBeck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, Driesen N, Ranganathan M, D’Souza D, Taylor M, Krystal JH, Howes OD. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open 2020, 3: e204693. PMID: 32437573, PMCID: PMC7243091, DOI: 10.1001/jamanetworkopen.2020.4693.
• Differential Effects of Childhood Vs. Adulthood Trauma in Cannabinoid Receptor Type 1 (CB1R) Availability in Post-Traumatic Stress Disorder (PTSD): A Review of Literature and Pilot Positron Emission Tomography (PET) StudyNia A, D'Souza C, Cosgrove K, Pietrzak R, Harpaz-Rotem I. Differential Effects of Childhood Vs. Adulthood Trauma in Cannabinoid Receptor Type 1 (CB1R) Availability in Post-Traumatic Stress Disorder (PTSD): A Review of Literature and Pilot Positron Emission Tomography (PET) Study. Biological Psychiatry 2020, 87: s381. DOI: 10.1016/j.biopsych.2020.02.976.
• Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in HumansHu Y, Ranganathan M, Shu C, Liang X, Ganesh S, Osafo-Addo A, Yan C, Zhang X, Aouizerat BE, Krystal JH, D’Souza D, Xu K. Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Scientific Reports 2020, 10: 3450. PMID: 32103029, PMCID: PMC7044203, DOI: 10.1038/s41598-020-59827-1.
• Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycinAbdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D’Souza D, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 2020, 45: 990-997. PMID: 32092760, PMCID: PMC7162891, DOI: 10.1038/s41386-020-0644-9.
• In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PETRadhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.
• Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposureD'Souza DC, Ganesh S, Cortes-Briones J, Campbell MH, Emmanuel MK. Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. Psychological Medicine 2019, 50: 2452-2459. PMID: 31615592, DOI: 10.1017/s0033291719002721.
• Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humansRanganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D’Souza D. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2019, 236: 3209-3219. PMID: 31187152, DOI: 10.1007/s00213-019-05273-5.
• Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controlsRoach BJ, D'Souza DC, Ford JM, Mathalon DH. Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls. NeuroImage Clinical 2019, 23: 101878. PMID: 31228795, PMCID: PMC6587022, DOI: 10.1016/j.nicl.2019.101878.
• Medical Marijuana: What Physicians Need to Know.Radhakrishnan R, Ranganathan M, D'Souza DC. Medical Marijuana: What Physicians Need to Know. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31087827, DOI: 10.4088/jcp.18ac12537.
• 20.1 BEHAVIORAL, COGNITIVE, AND PSYCHOPHYSIOLOGICAL CHARACTERIZATION AND SHORT-TERM COURSE OF CANNABINOID- INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP)D’Souza D, KL V, Tikka S, Raj J, Gahalout R, Skosnik P, Luddy C, Goyal N, Khess C, Sinha V, Ram D, Ganesh S, Cortes-Briones J. 20.1 BEHAVIORAL, COGNITIVE, AND PSYCHOPHYSIOLOGICAL CHARACTERIZATION AND SHORT-TERM COURSE OF CANNABINOID- INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP). Schizophrenia Bulletin 2019, 45: s121-s122. PMCID: PMC6455882, DOI: 10.1093/schbul/sbz022.080.
• O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNINGGanesh S, Vidya K, Tikka S, Raj J, Gahalout R, Skosnik P, Luddy C, Goyal N, Ram D, D’Souza D, Cortes-Briones J. O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNING. Schizophrenia Bulletin 2019, 45: s194-s194. PMCID: PMC6455269, DOI: 10.1093/schbul/sbz021.258.
• S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGINGRadhakrishnan R, Skosnik P, Ranganathan M, Naganawa M, Finnema S, Esterlis I, Huang Y, Nabulsi N, Carson R, D’Souza D. S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. Schizophrenia Bulletin 2019, 45: s310-s311. PMCID: PMC6455499, DOI: 10.1093/schbul/sbz020.558.
• Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysisGupta S, De Aquino JP, D’Souza D, Ranganathan M. Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. Psychopharmacology 2019, 236: 2635-2640. PMID: 30919005, PMCID: PMC6697616, DOI: 10.1007/s00213-019-05235-x.
• Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in AdolescenceOrr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D'Souza D, Allgaier N, Banaschewski T, Bokde ALW, Bromberg U, Büchel C, Quinlan E, Conrod P, Desrivières S, Flor H, Frouin V, Gowland P, Heinz A, Ittermann B, Martinot JL, Martinot MP, Nees F, Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Radhakrishnan R, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence. Journal Of Neuroscience 2019, 39: 1817-1827. PMID: 30643026, PMCID: PMC6407302, DOI: 10.1523/jneurosci.3375-17.2018.
• Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trialD'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry 2018, 6: 35-45. PMID: 30528676, DOI: 10.1016/s2215-0366(18)30427-9.
• The Association Between Cannabinoids and PsychosisTikka S, D’Souza D. The Association Between Cannabinoids and Psychosis. 2018, 127-155. DOI: 10.1007/978-3-319-90365-1_14.
• Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA studyBreier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research 2018, 206: 291-299. PMID: 30478008, DOI: 10.1016/j.schres.2018.11.002.
• Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid SystemGanesh S, Vidya K, Rashid A, Singh J, D’Souza D. Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid System. Current Addiction Reports 2018, 5: 418-427. DOI: 10.1007/s40429-018-0233-8.
• The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humansBoggs DL, Cortes-Briones JA, Surti T, Luddy C, Ranganathan M, Cahill JD, Sewell AR, D’Souza D, Skosnik PD. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans. Journal Of Psychopharmacology 2018, 32: 1308-1318. PMID: 30255720, DOI: 10.1177/0269881118799953.
• 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot J, Henry S, Planeta B, Lin S, Ropchan J, Williams W, Morris E, D’Souza D, Huang Y, Carson R, Matuskey D. 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET. Journal Of Clinical And Translational Science 2018, 2: 3-4. PMCID: PMC6799074, DOI: 10.1017/cts.2018.44.
• 168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis WithdrawalSkosnik P, Cortes-Briones J, Creatura G, Morgan P, Ranganathan M, Deaso E, Surti T, D'Souza D. 168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal. Biological Psychiatry 2018, 83: s68. DOI: 10.1016/j.biopsych.2018.02.186.
• The Psychiatric Consequences of CannabinoidsDe Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza D. The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics 2018, 40: 1448-1456. PMID: 29678279, DOI: 10.1016/j.clinthera.2018.03.013.
• Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. Journal Of Nuclear Medicine 2018, 59: 1445-1450. PMID: 29626125, PMCID: PMC6126437, DOI: 10.2967/jnumed.117.206516.
• The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trialBoggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D’Souza D, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018, 235: 1923-1932. PMID: 29619533, DOI: 10.1007/s00213-018-4885-9.
• 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDYBreier A, Dickerson F, Buchanan R, Marder S, Neuchterlein K, D’Souza D, Francis M, Radnovich A, Yolken R, Preskorn S, Macaluso M, Yang Z, Mehdyoun N, Kakar R, Dunn W, Hoffmeyer D, Maguire G. 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY. Schizophrenia Bulletin 2018, 44: s63-s63. PMCID: PMC5888721, DOI: 10.1093/schbul/sby014.162.
• 17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.Ranganathan M, D’Souza D, Cortes-Briones J, Skosnik P. 17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS. Schizophrenia Bulletin 2018, 44: s27-s27. PMCID: PMC5887318, DOI: 10.1093/schbul/sby014.066.
• Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humansSkosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology 2018, 135: 412-423. PMID: 29604295, PMCID: PMC6091633, DOI: 10.1016/j.neuropharm.2018.03.036.
• Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic PsychedelicsSchindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.
• Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia SubjectsD’Souza D, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, Ahn K, Bielen K, Carbuto M, Deaso E, D’Souza D, Ranganathan M, Naganawa M, Ranganathan M, D’Souza D, Nabulsi N, Zheng M, Lin S, Huang Y, Carson R, Driesen N, Ahn K, Morgan P, Suckow R, He G, McCarthy G, Krystal J, Johannesen J, Kenney J, Gelernter J, Gueorguieva R, Pittman B. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84: 413-421. PMID: 29499855, PMCID: PMC6068006, DOI: 10.1016/j.biopsych.2017.12.019.
• Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory SettingsCahill J, Gupta S, Cortes-Briones J, Radhakrishnan R, Sherif M, D'Souza D. Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory Settings. 2018, 75-128. DOI: 10.1016/b978-0-12-804791-0.00004-5.
• Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?Taylor JJ, Krystal JH, D'Souza DC, Gerrard JL, Corlett PR. Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS? Schizophrenia Research 2017, 195: 455-462. PMID: 28969932, PMCID: PMC8141945, DOI: 10.1016/j.schres.2017.09.020.
• Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophreniaHamilton HK, D'Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, Bhakta S, Ranganathan M, Mathalon DH. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia. Schizophrenia Research 2017, 191: 87-94. PMID: 28711472, PMCID: PMC5745273, DOI: 10.1016/j.schres.2017.06.040.
• Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical TrialMohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.
• Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal informationRanganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Sewell R, Skosnik PD, D'Souza DC. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 79: 176-183. PMID: 28642081, DOI: 10.1016/j.pnpbp.2017.06.019.
• 63 Cannabinoid-Mediated Disruption of Sensory Gating and Neural Network Oscillations: A Translational Study in Humans and RatsSkosnik P, Hajos M, Cortes-Briones J, Pittman B, Sewell A, D’Souza D, Ranganathan M. 63 Cannabinoid-Mediated Disruption of Sensory Gating and Neural Network Oscillations: A Translational Study in Humans and Rats. Biological Psychiatry 2017, 81: s26-s27. DOI: 10.1016/j.biopsych.2017.02.074.
• 67 Ketamine-induced Changes in Neural Noise and their Relationship to Psychosis-like SymptomsCortes-Briones J, Skosnik P, D’Souza D, Abdallah C, Petrakis I, Krystal J. 67 Ketamine-induced Changes in Neural Noise and their Relationship to Psychosis-like Symptoms. Biological Psychiatry 2017, 81: s28. DOI: 10.1016/j.biopsych.2017.02.078.
• 962 In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging StudyRadhakrishnan R, Skosnik P, Finnema S, Rotolo R, Forselius-Bielen K, Creatura G, Nabulsi N, Carson R, D׳Souza D. 962 In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging Study. Biological Psychiatry 2017, 81: s389. DOI: 10.1016/j.biopsych.2017.02.688.
• Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophreniaBoggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia. Schizophrenia Research 2017, 194: 62-69. PMID: 28392208, PMCID: PMC5630481, DOI: 10.1016/j.schres.2017.03.047.
• Opposing Effects of Cannabis Use on Electroencephalographic Measures of Auditory Repetition Suppression in Schizophrenia and Healthy ControlsSkosnik PD, D’Souza D. Opposing Effects of Cannabis Use on Electroencephalographic Measures of Auditory Repetition Suppression in Schizophrenia and Healthy Controls. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 209-211. PMID: 29528290, DOI: 10.1016/j.bpsc.2017.03.004.
• 208. Predictors of Cannabis-Induced PsychosisRanganathan M, Morgan C, Di Forti M, Curran H, Dsouza D. 208. Predictors of Cannabis-Induced Psychosis. Schizophrenia Bulletin 2017, 43: s106-s106. PMCID: PMC5475744, DOI: 10.1093/schbul/sbx021.286.
• Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D’Souza D. Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. Molecular Psychiatry 2017, 22: 1633-1640. PMID: 28242871, DOI: 10.1038/mp.2017.6.
• The role of psychedelics in palliative care reconsidered: A case for psilocybinKelmendi B, Corlett P, Ranganathan M, D’Souza C, Krystal JH. The role of psychedelics in palliative care reconsidered: A case for psilocybin. Journal Of Psychopharmacology 2016, 30: 1212-1214. PMID: 27909173, DOI: 10.1177/0269881116675781.
• A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications.Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal Of Clinical Psychiatry 2016, 77: 1050-64. PMID: 27561138, DOI: 10.4088/jcp.15r10036.
• Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNOGirgis RR, Slifstein M, D’Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology 2016, 233: 3503-3512. PMID: 27525990, PMCID: PMC5035321, DOI: 10.1007/s00213-016-4382-y.
• Marijuana and Madness: Associations Between Cannabinoids and PsychosisRanganathan M, Skosnik PD, D’Souza D. Marijuana and Madness: Associations Between Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 511-513. PMID: 26970361, DOI: 10.1016/j.biopsych.2016.02.007.
• Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trialsDeWorsop D, Creatura G, Bluez G, Thurnauer H, Forselius-Bielen K, Ranganathan M, Deaso E, Bhat JA, D’Souza D. Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. Drug And Alcohol Dependence 2016, 163: 24-30. PMID: 27068252, DOI: 10.1016/j.drugalcdep.2016.02.045.
• Human Laboratory Studies on Cannabinoids and PsychosisSherif M, Radhakrishnan R, D’Souza D, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 526-538. PMID: 26970363, DOI: 10.1016/j.biopsych.2016.01.011.
• Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From CannabisD’Souza D, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2016, 1: 60-67. PMID: 26858993, PMCID: PMC4742341, DOI: 10.1016/j.bpsc.2015.09.008.
• Synthetic Cannabinoids: The Pharmacokinetics and Pharmacodynamics of Spice and Other Synthetic CannabinoidsGupta A, D'Souza D. Synthetic Cannabinoids: The Pharmacokinetics and Pharmacodynamics of Spice and Other Synthetic Cannabinoids. 2016, 213-248. DOI: 10.4135/9781473922143.n14.
• The early identification of psychosis: can lessons be learnt from cardiac stress testing?Gupta S, Ranganathan M, D’Souza D. The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology 2015, 233: 19-37. PMID: 26566609, PMCID: PMC4703558, DOI: 10.1007/s00213-015-4143-3.
• Marijuana Legalization: Impact on Physicians and Public HealthWilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana Legalization: Impact on Physicians and Public Health. Annual Review Of Medicine 2015, 67: 1-14. PMID: 26515984, PMCID: PMC4900958, DOI: 10.1146/annurev-med-050214-013454.
• Reduced Brain Cannabinoid Receptor Availability in SchizophreniaRanganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D’Souza D. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry 2015, 79: 997-1005. PMID: 26432420, PMCID: PMC4884543, DOI: 10.1016/j.biopsych.2015.08.021.
• Medical Marijuana: Is the Cart Before the Horse?D'Souza DC, Ranganathan M. Medical Marijuana: Is the Cart Before the Horse? JAMA 2015, 313: 2431-2432. PMID: 26103026, DOI: 10.1001/jama.2015.6407.
• The Formation of Marijuana Risk Perception in a Population of Substance Abusing PatientsWilkinson ST, van Schalkwyk GI, Davidson L, D’Souza D. The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. Psychiatric Quarterly 2015, 87: 177-187. PMID: 25982082, DOI: 10.1007/s11126-015-9369-z.
• Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of AmphetamineAhn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology 2015, 40: 2822-2831. PMID: 25953357, PMCID: PMC4864658, DOI: 10.1038/npp.2015.132.
• Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in HumansCortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC. Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans. Neuropsychopharmacology 2015, 40: 2124-2134. PMID: 25709097, PMCID: PMC4613601, DOI: 10.1038/npp.2015.53.
• Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging StudySlifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D’Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A. Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging Study. JAMA Psychiatry 2015, 72: 316-324. PMID: 25651194, PMCID: PMC4768742, DOI: 10.1001/jamapsychiatry.2014.2414.
• The Psychosis-like Effects of Δ9-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy HumansCortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D’Souza D. The Psychosis-like Effects of Δ9-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. Biological Psychiatry 2015, 78: 805-813. PMID: 25913109, PMCID: PMC4627857, DOI: 10.1016/j.biopsych.2015.03.023.
• GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THCRadhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology 2015, 40: 2047-2056. PMID: 25728472, PMCID: PMC4839528, DOI: 10.1038/npp.2015.58.
• Medicalization of Marijuana—ReplyWilkinson ST, D’Souza D. Medicalization of Marijuana—Reply. JAMA 2014, 312: 1931-1932. PMID: 25387198, DOI: 10.1001/jama.2014.12569.
• Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis UsersSkosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF. Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users. Neuropsychopharmacology 2014, 39: 3087-3099. PMID: 24990428, PMCID: PMC4229582, DOI: 10.1038/npp.2014.166.
• Problems With the Medicalization of MarijuanaWilkinson ST, D’Souza D. Problems With the Medicalization of Marijuana. JAMA 2014, 311: 2377-2378. PMID: 24845238, PMCID: PMC6248328, DOI: 10.1001/jama.2014.6175.
• Gone to Pot – A Review of the Association between Cannabis and PsychosisRadhakrishnan R, Wilkinson ST, D’Souza D. Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers In Psychiatry 2014, 5: 54. PMID: 24904437, PMCID: PMC4033190, DOI: 10.3389/fpsyt.2014.00054.
• Testing differences in the activity of event-related potential sources: Important implications for clinical researchersCortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D’Souza D, Skosnik PD. Testing differences in the activity of event-related potential sources: Important implications for clinical researchers. Clinical Neurophysiology 2014, 126: 215-218. PMID: 24840905, DOI: 10.1016/j.clinph.2014.04.008.
• Impact of Cannabis Use on the Development of Psychotic DisordersWilkinson ST, Radhakrishnan R, D’Souza D. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports 2014, 1: 115-128. PMID: 25767748, PMCID: PMC4352721, DOI: 10.1007/s40429-014-0018-7.
• SPICING THING UP – WHAT CAN WE LEARN FROM SYNTHETIC CANNABINOIDS ABOUT THE LINK BETWEEN CANNABINOIDS AND PSYCHOSISD'Souza D, Spaderna M, Addy P, Ranganathan M. SPICING THING UP – WHAT CAN WE LEARN FROM SYNTHETIC CANNABINOIDS ABOUT THE LINK BETWEEN CANNABINOIDS AND PSYCHOSIS. Schizophrenia Research 2014, 153: s32. DOI: 10.1016/s0920-9964(14)70106-9.
• 5:30 PM IN VIVO EVIDENCE OF REDUCED BRAIN CANNABINOID RECEPTORS IN SCHIZOPHRENIAD'Souza D, Thurnauer H, Ranganathan M, Cortes J, Radhakrishnan R, Carson R, Huang Y, Planeta-Wilson B. 5:30 PM IN VIVO EVIDENCE OF REDUCED BRAIN CANNABINOID RECEPTORS IN SCHIZOPHRENIA. Schizophrenia Research 2014, 153: s52. DOI: 10.1016/s0920-9964(14)70171-9.
• Poster #T56 LEARN BEFORE YOU BURN: THC IMPAIRS ENCODING BUT NOT RETRIEVAL OF VERBAL INFORMATIOND'Souza D, Ranganathan M, Addy P, Thurnauer H, Schnakenberg A, Pittman B, Radhakrishnan R, Skosnik P, Sewell R. Poster #T56 LEARN BEFORE YOU BURN: THC IMPAIRS ENCODING BUT NOT RETRIEVAL OF VERBAL INFORMATION. Schizophrenia Research 2014, 153: s308-s309. DOI: 10.1016/s0920-9964(14)70873-4.
• Poster #S268 DECREASED BRAIN CANNABINOID RECEPTOR (CB1R) AVAILABILITY IN CANNABIS DEPENDENCE RAPIDLY NORMALIZES WITH ABSTINENCED'Souza D, Cortes J, Ranganathan M, Thurnauer H, Planeta B, Radhakrishnan R, Huang Y, Carson R, Skosnik P. Poster #S268 DECREASED BRAIN CANNABINOID RECEPTOR (CB1R) AVAILABILITY IN CANNABIS DEPENDENCE RAPIDLY NORMALIZES WITH ABSTINENCE. Schizophrenia Research 2014, 153: s187. DOI: 10.1016/s0920-9964(14)70547-x.
• Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholismRanganathan M, Sewell RA, Carbuto M, Elander J, Schnakenberg A, Radhakrishnan R, Pittman B, D’Souza D. Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. Psychopharmacology 2014, 231: 2385-2393. PMID: 24424782, DOI: 10.1007/s00213-013-3402-4.
• Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in HumansMathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D’Souza D. Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers In Psychiatry 2014, 5: 3. PMID: 24478731, PMCID: PMC3900858, DOI: 10.3389/fpsyt.2014.00003.
• Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Current Pharmaceutical Design 2014, 20: 5077-92. PMID: 24345265, PMCID: PMC4442779, DOI: 10.2174/1381612819666131216121019.
• Chapter Fourteen Cannabis, Cannabinoids, and the Association with PsychosisRadhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.
• In Vivo Evidence for β2 Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared With Nonsmokers With SchizophreniaEsterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D’Souza D. In Vivo Evidence for β2 Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared With Nonsmokers With Schizophrenia. Biological Psychiatry 2013, 76: 495-502. PMID: 24360979, PMCID: PMC4019710, DOI: 10.1016/j.biopsych.2013.11.001.
• Pilot study of Intravenous Nicotine Effects on Cognitive Performance in SchizophreniaBoggs DL, Ranganathan M, Sewell RA, Madonick S, D'Souza DC. Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia. Schizophrenia Research 2013, 150: 323-324. PMID: 23953216, DOI: 10.1016/j.schres.2013.07.045.
• Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.Boggs DL, Ranganathan M, Boggs AA, Bihday CM, Peluse BE, D'Souza DC. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. The Primary Care Companion For CNS Disorders 2013, 15 PMID: 24392257, PMCID: PMC3869609, DOI: 10.4088/pcc.13l01519.
• The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and ConnectivityDriesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, Gueorguieva R, He G, Leung HC, Ramani R, Anticevic A, Suckow RF, Morgan PT, Krystal JH. The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and Connectivity. Neuropsychopharmacology 2013, 38: 2613-2622. PMID: 23856634, PMCID: PMC3828532, DOI: 10.1038/npp.2013.170.
• Spicing things up: synthetic cannabinoidsSpaderna M, Addy PH, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013, 228: 525-540. PMID: 23836028, PMCID: PMC3799955, DOI: 10.1007/s00213-013-3188-4.
• Effect of a Nicotine Vaccine on Nicotine Binding to β2*-Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco SmokersEsterlis I, Hannestad JO, Perkins E, Bois F, D’Souza D, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O’Malley S. Effect of a Nicotine Vaccine on Nicotine Binding to β2*-Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco Smokers. American Journal Of Psychiatry 2013, 170: 399-407. PMID: 23429725, PMCID: PMC3738000, DOI: 10.1176/appi.ajp.2012.12060793.
• Commentary on Hermanns‐Clausen et al. (2013): Spicing things up – the emerging phenomenon of synthetic cannabinoid useAddy PH, D'Souza D. Commentary on Hermanns‐Clausen et al. (2013): Spicing things up – the emerging phenomenon of synthetic cannabinoid use. Addiction 2013, 108: 545-546. PMID: 23418659, DOI: 10.1111/add.12098.
• Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humansDriesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18: 1199-1204. PMID: 23337947, PMCID: PMC3646075, DOI: 10.1038/mp.2012.194.
• Efficacy of pimozide augmentation for clozapine partial responders with schizophreniaGunduz-Bruce H, Oliver S, Gueorguieva R, Forselius-Bielen K, D'Souza DC, Zimolo Z, Tek C, Kaliora S, Ray S, Petrides G. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research 2012, 143: 344-347. PMID: 23219861, DOI: 10.1016/j.schres.2012.11.008.
• Acute effects of THC on time perception in frequent and infrequent cannabis usersSewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza D. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2012, 226: 401-413. PMID: 23179965, PMCID: PMC3581701, DOI: 10.1007/s00213-012-2915-6.
• Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot StudyD'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology 2012, 38: 492-503. PMID: 23093223, PMCID: PMC3547200, DOI: 10.1038/npp.2012.208.
• Glycine treatment of the risk syndrome for psychosis: Report of two pilot studiesWoods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.
• Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in HumansRanganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans. Biological Psychiatry 2012, 72: 871-879. PMID: 22817868, PMCID: PMC3638802, DOI: 10.1016/j.biopsych.2012.06.012.
• The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in HumansSkosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O'Donnell BF. The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans. Neuropsychopharmacology 2012, 37: 2184-2193. PMID: 22713908, PMCID: PMC3422484, DOI: 10.1038/npp.2012.65.
• Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for SchizophreniaD'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia. Biological Psychiatry 2012, 72: 785-794. PMID: 22717030, DOI: 10.1016/j.biopsych.2012.05.009.
• Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup TS. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal Of Clinical Psychiatry 2012, 73: 1016-22. PMID: 22687548, PMCID: PMC3746329, DOI: 10.4088/jcp.11m07100.
• Cannabinoids, Working Memory, and SchizophreniaSkosnik PD, Ranganathan M, D'Souza DC. Cannabinoids, Working Memory, and Schizophrenia. Biological Psychiatry 2012, 71: 662-663. PMID: 22449262, DOI: 10.1016/j.biopsych.2012.02.028.
• GENETIC MODERATION OF THE PSYCHOTOMIMETIC AND AMNESTIC EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL IN THE LABORATORYD'Souza D. GENETIC MODERATION OF THE PSYCHOTOMIMETIC AND AMNESTIC EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL IN THE LABORATORY. Schizophrenia Research 2012, 136: s32. DOI: 10.1016/s0920-9964(12)70116-0.
• Lower β2*-Nicotinic Acetylcholine Receptor Availability in Smokers With SchizophreniaD'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Lower β2*-Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia. American Journal Of Psychiatry 2012, 169: 326-334. PMID: 22193533, PMCID: PMC3881431, DOI: 10.1176/appi.ajp.2011.11020189.
• Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in HumansD'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in Humans. Neuropsychopharmacology 2012, 37: 1632-1646. PMID: 22334121, PMCID: PMC3358754, DOI: 10.1038/npp.2012.8.
• Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humansRanganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal Of Neuropsychopharmacology 2012, 15: 1251-1264. PMID: 22243563, DOI: 10.1017/s1461145711001830.
• Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and TreatmentAddy P, Radhakrishnan R, Cortes J, D’Souza D. Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment. FOCUS The Journal Of Lifelong Learning In Psychiatry 2012, 10: 140-153. DOI: 10.1176/appi.focus.10.2.140.
• Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study.Ralevski E, Perry EB, D'Souza DC, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study. Nicotine & Tobacco Research 2011, 14: 596-606. PMID: 22180582, PMCID: PMC6281082, DOI: 10.1093/ntr/ntr258.
• Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary EvidenceD'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J. Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology 2011, 37: 1036-1046. PMID: 22113087, PMCID: PMC3280648, DOI: 10.1038/npp.2011.295.
• Glutamatergic Modulation of Auditory Information Processing in the Human BrainGunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, Ford JM, Krystal JH, Mathalon DH. Glutamatergic Modulation of Auditory Information Processing in the Human Brain. Biological Psychiatry 2011, 71: 969-977. PMID: 22036036, PMCID: PMC3290754, DOI: 10.1016/j.biopsych.2011.09.031.
• The acute effects of cannabinoids in patients with psychotic illnessHenquet C, Sewell A, Kuepper R, Ranganathan M, D’Souza D. The acute effects of cannabinoids in patients with psychotic illness. 2011, 198-209. DOI: 10.1017/cbo9780511706080.019.
• The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case historiesCarbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.
• Erratum: Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol DependenceKrystal J, Petrakis I, Limoncelli D, Nappi S, Trevisan L, Pittman B, D'Souza D. Erratum: Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol Dependence. Neuropsychopharmacology 2011, 36: 911-911. PMCID: PMC3055722, DOI: 10.1038/npp.2011.2.
• Plate sectionCastle D, Murray R, D'Souza D. Plate section. 2011 DOI: 10.1017/cbo9780511706080.023.
• PrefaceCastle D, Murray R, D'Souza D. Preface. 2011, xi-xii. DOI: 10.1017/cbo9780511706080.001.
• Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol DependenceKrystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B, D'Souza DC. Characterization of the Interactive Effects of Glycine and D-Cycloserine in Men: Further Evidence for Enhanced NMDA Receptor Function Associated with Human Alcohol Dependence. Neuropsychopharmacology 2010, 36: 701-710. PMID: 21124304, PMCID: PMC3055693, DOI: 10.1038/npp.2010.203.
• Probing GABA Receptor Function in Schizophrenia with IomazenilAhn K, Gil R, Seibyl J, Sewell RA, D'Souza DC. Probing GABA Receptor Function in Schizophrenia with Iomazenil. Neuropsychopharmacology 2010, 36: 677-683. PMID: 21068719, PMCID: PMC3055690, DOI: 10.1038/npp.2010.198.
• Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation ScaleSewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale. Schizophrenia Research 2010, 124: 1-12. PMID: 20855185, DOI: 10.1016/j.schres.2010.08.036.
• Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal Of Clinical Psychiatry 2010, 71: 1475-81. PMID: 20816042, DOI: 10.4088/jcp.09m05950gry.
• Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and AntagonistsKrystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.
• Modeling analysis of the CB1 PET tracer [11C]OMAR in rhesus monkeys and humansNormandin M, Weinzimmer D, Ropchan J, Labaree D, Lin K, Mason N, Carson R, D'Souza D, Neumeister A, Huang Y. Modeling analysis of the CB1 PET tracer [11C]OMAR in rhesus monkeys and humans. NeuroImage 2010, 52: s13. DOI: 10.1016/j.neuroimage.2010.04.198.
• High dose D-serine in the treatment of schizophreniaKantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC. High dose D-serine in the treatment of schizophrenia. Schizophrenia Research 2010, 121: 125-130. PMID: 20541910, PMCID: PMC3111070, DOI: 10.1016/j.schres.2010.05.012.
• Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofreniaSewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal Of Psychiatry 2010, 32: 515-530. PMID: 20512267, DOI: 10.1590/s1516-44462010000500005.
• Capgras Syndrome Induced by Ketamine in a Healthy SubjectCorlett PR, D'Souza DC, Krystal JH. Capgras Syndrome Induced by Ketamine in a Healthy Subject. Biological Psychiatry 2010, 68: e1-e2. PMID: 20385373, PMCID: PMC3721067, DOI: 10.1016/j.biopsych.2010.02.015.
• FEASIBILITY STUDY OF MULTI-SITE COGNITIVE REMEDIATION IN THE SCHIZOPHRENIA TRIALS NETWORK (CRSTN)Keefe R, Vinogradov S, Medalia A, Buckley P, Caroff S, D'Souza D, Harvey P, Graham K, Marder S, Miller D, Olson S, Patel J, Velligan D, Walker T, Haim A, Stroup S. FEASIBILITY STUDY OF MULTI-SITE COGNITIVE REMEDIATION IN THE SCHIZOPHRENIA TRIALS NETWORK (CRSTN). Schizophrenia Research 2010, 117: 394. DOI: 10.1016/j.schres.2010.02.712.
• Modelling psychosisCurran HV, D’Souza D, Robbins TW, Fletcher P. Modelling psychosis. Psychopharmacology 2009, 206: 513-514. PMID: 19756521, DOI: 10.1007/s00213-009-1663-8.
• Cannabis and psychosis/schizophrenia: human studiesD’Souza D, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives Of Psychiatry And Clinical Neuroscience 2009, 259: 413-431. PMID: 19609589, PMCID: PMC2864503, DOI: 10.1007/s00406-009-0024-2.
• NMDA Receptor Antagonist Ketamine Produces Opposing Effects on Resting and Task-Related Brain Activation During Working Memory in HumansDriesen N, McCarthy G, Bhagwagar Z, Calhoun V, D'Souza D, Holub J, Morgan P, Krystal J. NMDA Receptor Antagonist Ketamine Produces Opposing Effects on Resting and Task-Related Brain Activation During Working Memory in Humans. NeuroImage 2009, 47: s145. DOI: 10.1016/s1053-8119(09)71458-2.
• Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophreniaKrystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.
• Cannabinoids and psychosisSewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry 2009, 21: 152-162. PMID: 19367509, DOI: 10.1080/09540260902782802.
• The effects of cannabinoids on serum cortisol and prolactin in humansRanganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D’Souza D. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology 2008, 203: 737. PMID: 19083209, PMCID: PMC2863108, DOI: 10.1007/s00213-008-1422-2.
• Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humansD’Souza D, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 2008, 202: 569. PMID: 18807247, PMCID: PMC2791800, DOI: 10.1007/s00213-008-1333-2.
• LABORATORY STUDIES OF DELTA-9-THC IN HUMANS: RELEVANCE TO SCHIZOPHRENIAD'Souza D, Mathalon D, Perry E. LABORATORY STUDIES OF DELTA-9-THC IN HUMANS: RELEVANCE TO SCHIZOPHRENIA. Schizophrenia Research 2008, 102: 1. DOI: 10.1016/s0920-9964(08)70003-3.
• Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humansD’Souza D, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198: 587-603. PMID: 18228005, PMCID: PMC2878815, DOI: 10.1007/s00213-007-1042-2.
• Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of CannabisD'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology 2008, 33: 2505-2516. PMID: 18185500, PMCID: PMC3799954, DOI: 10.1038/sj.npp.1301643.
• Absence of Significant Interactive Effects of High‐Dose d‐Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the GlycineB Site of NMDA Glutamate ReceptorsTrevisan L, Petrakis IL, Pittman B, Gueorguieva R, D’Souza D, Perry E, Limoncelli D, Krystal JH. Absence of Significant Interactive Effects of High‐Dose d‐Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the GlycineB Site of NMDA Glutamate Receptors. Alcohol Clinical And Experimental Research 2007, 32: 36-42. PMID: 18028532, DOI: 10.1111/j.1530-0277.2007.00543.x.
• Psychiatric safety of ketamine in psychopharmacology researchPerry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.
• Cannabinoids and PsychosisD'Souza DC. Cannabinoids and Psychosis. 2007, 78: 289-326. PMID: 17349865, DOI: 10.1016/s0074-7742(06)78010-2.
• Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human SubjectsNeumeister A, Carson R, Henry S, Planeta-Wilson B, Binneman B, Maguire RP, Luckenbaugh DA, D'Souza C, Krystal JH, Frost JJ. Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects. Journal Of Clinical Psychopharmacology 2006, 26: 595-599. PMID: 17110816, DOI: 10.1097/01.jcp.0000245558.14284.aa.
• The acute effects of cannabinoids on memory in humans: a reviewRanganathan M, D’Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188: 425-444. PMID: 17019571, DOI: 10.1007/s00213-006-0508-y.
• Enhanced Sensitivity to the Euphoric Effects of Alcohol in SchizophreniaD'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia. Neuropsychopharmacology 2006, 31: 2767-2775. PMID: 16985503, DOI: 10.1038/sj.npp.1301207.
• The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophreniaKrystal JH, D’Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10: 235-252. PMID: 17197373, DOI: 10.1007/bf03033360.
• Greater vulnerability to the amnestic effects of ketamine in malesMorgan CJ, Perry EB, Cho HS, Krystal JH, D’Souza D. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187: 405-414. PMID: 16896964, DOI: 10.1007/s00213-006-0409-0.
• Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorderSrihari VH, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder. Schizophrenia Research 2006, 82: 261-264. PMID: 16442782, DOI: 10.1016/j.schres.2005.11.022.
• Psychoactive DrugsD'Souza D, Krystal J. Psychoactive Drugs. 2006 DOI: 10.1002/0470018860.s00599.
• Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of AlcoholismKrystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC. Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. Neuropsychopharmacology 2006, 31: 1793-1800. PMID: 16395307, DOI: 10.1038/sj.npp.1300994.
• [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokersStaley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.
• γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and DissociationD’Souza D, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH. γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation. Biological Psychiatry 2005, 59: 128-137. PMID: 16140281, DOI: 10.1016/j.biopsych.2005.06.020.
• Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive FunctionKrystal JH, Perry EB, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, MacDougall L, Abi-Saab W, D’Souza D. Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function. JAMA Psychiatry 2005, 62: 985-995. PMID: 16143730, DOI: 10.1001/archpsyc.62.9.985.
• Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addictionD’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.
• Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamineCho HS, D’Souza D, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 2005, 179: 136-143. PMID: 15682309, DOI: 10.1007/s00213-004-2066-5.
• Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or DependencePerry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsKrystal JH, Abi-Saab W, Perry E, D’Souza D, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2004, 179: 303-309. PMID: 15309376, DOI: 10.1007/s00213-004-1982-8.
• The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for PsychosisD'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004, 29: 1558-1572. PMID: 15173844, DOI: 10.1038/sj.npp.1300496.
• Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophreniaD'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.
• Blood dyscrasiasCho H, Krystal J, D’Souza D. Blood dyscrasias. 2004, 221-238. DOI: 10.1093/med/9780198527480.003.0012.
• Nicotine effects on brain function and functional connectivity in schizophreniaJacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biological Psychiatry 2004, 55: 850-858. PMID: 15050867, DOI: 10.1016/j.biopsych.2003.12.023.
• NMDA Receptor Antagonism and the Ethanol Intoxication SignalKRYSTAL JH, PETRAKIS IL, KRUPITSKY E, SCHÜTZ C, TREVISAN L, D'SOUZA DC. NMDA Receptor Antagonism and the Ethanol Intoxication Signal. Annals Of The New York Academy Of Sciences 2003, 1003: 176-184. PMID: 14684445, DOI: 10.1196/annals.1300.010.
• S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosisKrystal J, D'Souza D, Mathalon D, Belger A, Perry E. S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosis. European Neuropsychopharmacology 2003, 13: s96. DOI: 10.1016/s0924-977x(03)91600-2.
• NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication developmentKrystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169: 215-233. PMID: 12955285, DOI: 10.1007/s00213-003-1582-z.
• N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerabilityKrystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.
• Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent PatientsKrystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS. Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent Patients. Neuropsychopharmacology 2003, 28: 2020-2028. PMID: 12888778, DOI: 10.1038/sj.npp.1300252.
• Cannabinoids and psychosis: Pharmacological studies with IV delta-9-THC in humansD'Souza D, Perry E, Riccardi P, Abi-Saab W, Krystal J. Cannabinoids and psychosis: Pharmacological studies with IV delta-9-THC in humans. Schizophrenia Research 2003, 60: 310. DOI: 10.1016/s0920-9964(03)80247-5.
• Impact of nicotine on brain function in smokers with schizophreniaJacobsen L, Mencl W, D'Souza D, Pugh K, Skudlarski P, Abi-Saab W, Krystal J. Impact of nicotine on brain function in smokers with schizophrenia. Schizophrenia Research 2003, 60: 223-224. DOI: 10.1016/s0920-9964(03)81196-9.
• Lithium CarbonateKhan S, Anand A, D'Souza D. Lithium Carbonate. 2003, 803-810. DOI: 10.1016/b0-12-226870-9/01162-x.
• Alcohol and Glutamate Neurotransmission in Humans: Implications for Reward, Dependence, and TreatmentKrystal J, Petrakis I, D'Souza D, Mason G, Trevisan L. Alcohol and Glutamate Neurotransmission in Humans: Implications for Reward, Dependence, and Treatment. 2002, 0: 389-398. DOI: 10.1385/1-59259-306-2:389.
• Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptomsAbi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.
• Comment on “ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor”Krystal J, D’Souza D. Comment on “ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor”. Biological Psychiatry 2001, 50: 555. PMID: 11600110, DOI: 10.1016/s0006-3223(01)01258-6.
• Lower prolactin bioactivity in unmedicated schizophrenic patientsWarner M, Walker A, D'Souza D, Lee D, Nasseri D, Peabody C. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Research 2001, 102: 249-254. PMID: 11440775, DOI: 10.1016/s0165-1781(01)00256-6.
• CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERSKrystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.
• Cannabinoid Antagonists: A Treatment in Search of an IllnessD'Souza D, Kosten T. Cannabinoid Antagonists: A Treatment in Search of an Illness. JAMA Psychiatry 2001, 58: 330-331. PMID: 11296092, DOI: 10.1001/archpsyc.58.4.330.
• Substance Abuse as a Risk Factor for Schizophrenia and Related DisordersBowers M, Boutros N, D’Souza D, Madonick S. Substance Abuse as a Risk Factor for Schizophrenia and Related Disorders. International Journal Of Mental Health 2001, 30: 33-57. DOI: 10.1080/00207411.2001.11449509.
• Psychopharmacological challenge studies in psychiatric researchD'Souza D, Krystal J. Psychopharmacological challenge studies in psychiatric research. International Review Of Psychiatry 2001, 13: 40-46. DOI: 10.1080/09540260020024187.
• Psychopharmacological challenge studies in psychiatric researchD'Souza D, Krystal J. Psychopharmacological challenge studies in psychiatric research. International Review Of Psychiatry 2001, 13: 40-46. DOI: 10.1080/09540260123077.
• IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humansD’Souza D, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper L, Zuzarte E, Charney D, Krystal J. IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry 2000, 47: 450-462. PMID: 10704956, DOI: 10.1016/s0006-3223(99)00133-x.
• Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CITLaruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biological Psychiatry 2000, 47: 371-379. PMID: 10704949, DOI: 10.1016/s0006-3223(99)00257-7.
• Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functionsKrystal J, Bennett A, Abi-Saab D, Belger A, Karper L, D’Souza D, Lipschitz D, Abi-Dargham A, Charney D. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry 2000, 47: 137-143. PMID: 10664830, PMCID: PMC10060085, DOI: 10.1016/s0006-3223(99)00097-9.
• The Emerging Neurobiology of Dissociative StatesKrystal J, Bremner J, D’Souza D, Anand A, Southwick S, Charney D. The Emerging Neurobiology of Dissociative States. 2000, 307-320. DOI: 10.1007/978-1-4615-4177-6_22.
• Cannabinoids & psychosis: Evidence from studies with I.V THC in schizophrenic patients and controlsD'Souza D, Abi-Saab W, Madonick S, Wray Y, Forselius K, MacDougall L, Brush L, Cassello K, Krystal J. Cannabinoids & psychosis: Evidence from studies with I.V THC in schizophrenic patients and controls. Schizophrenia Research 2000, 41: 33. DOI: 10.1016/s0920-9964(00)90371-2.
• Dose-response of acute ethanol administration in schizophrenic patients and controlsD'Souza D, Madonick S, Abi-Saab W, Wray Y, MacDougall L, Brush L, Cassello K, Krystal J. Dose-response of acute ethanol administration in schizophrenic patients and controls. Schizophrenia Research 2000, 41: 247. DOI: 10.1016/s0920-9964(00)90923-x.
• Ketamine and amphetamine interactions in healthy humans: Further insights into glutamate-dopamine interactionsKrystal J, D'Souza D, Belger A, Madonick S, Cossello K. Ketamine and amphetamine interactions in healthy humans: Further insights into glutamate-dopamine interactions. Schizophrenia Research 2000, 41: 235-236. DOI: 10.1016/s0920-9964(00)90891-0.
• Therapeutic Implications of the Hyperglutamatergic Effects of NMDA AntagonistsKrystal J, Belger A, D'Souza D, Anand A, Charney D, Aghajanian G, Moghaddam B. Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists. Neuropsychopharmacology 1999, 21: s143-s157. DOI: 10.1016/s0893-133x(99)00102-5.
• Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary reportBoutros N, Belger A, Campbell D, D’Souza C, Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Research 1999, 88: 119-130. PMID: 10622348, DOI: 10.1016/s0165-1781(99)00074-8.
• Symptom provocation studies in psychiatric disorders: scientific value, risks, and futureD’Souza D, Berman R, Krystal J, Charney D. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry 1999, 46: 1060-1080. PMID: 10536743, DOI: 10.1016/s0006-3223(99)00209-7.
• [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophreniaVerhoeff N, Soares J, D’Souza C, Gil R, Degen K, Abi-Dargham A, Zoghbi S, Fujita M, Rajeevan N, Seibyl J, Krystal J, van Dyck C, Charney D, Innis R. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research 1999, 91: 163-173. PMID: 10641580, DOI: 10.1016/s0925-4927(99)00027-x.
• NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric DisordersKrystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.
• CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy ControlsPetrakis I, Trevisan L, D'Souza C, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal J. CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls. Alcohol Clinical And Experimental Research 1999, 23: 1336. DOI: 10.1097/00000374-199908000-00007.
• CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving?Petrakis I, Trevisan L, D'Souza C, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal J. CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving? Alcohol Clinical And Experimental Research 1999, 23: 1336-1341. PMID: 10470976, DOI: 10.1111/j.1530-0277.1999.tb04355.x.
• Interactive effects of subanesthetic ketamine and haloperidol in healthy humansKrystal J, D’Souza D, Karper L, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers Jr. M, Vegso S, Heninger G, Charney D, Bowers M. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 1999, 145: 193-204. PMID: 10463321, DOI: 10.1007/s002130051049.
• No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in SchizophreniaAbi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin R, Seibyl J, Mawlawi O, de Erasquin G, Charney D, Innis R. No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia. Neuropsychopharmacology 1999, 20: 650-661. PMID: 10327433, DOI: 10.1016/s0893-133x(98)00107-9.
• Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patientsKrystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.
• EditorialKrystal JH, D'Souza DC. Editorial. Biological Psychiatry 1998, 44: 1075-1076. PMID: 9836009, DOI: 10.1016/s0006-3223(98)00284-4.
• The NMDA Antagonist Model for Schizophrenia: Promise and PitfallsAbi-Saab W, D'Souza D, Moghaddam B, Krystal J. The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls. Pharmacopsychiatry 1998, 31: 104-109. PMID: 9754841, DOI: 10.1055/s-2007-979354.
• 251. New perspectives in the basic and common pharmacology of cannabinoidergic systemsD'Souza D, Deadwyler S, Heishman S, Ménard J, Mathew R. 251. New perspectives in the basic and common pharmacology of cannabinoidergic systems. Biological Psychiatry 1998, 43: s75. DOI: 10.1016/s0006-3223(98)90699-0.
• 435. Dose-response of THC effects in schizophrenics and healthy controlsD'Souza D, Belger A, Abi-Saab W, Adams S, Gil R, Larvey K, Cassello K, Sernyak M, Krystal J. 435. Dose-response of THC effects in schizophrenics and healthy controls. Biological Psychiatry 1998, 43: s130-s131. DOI: 10.1016/s0006-3223(98)90883-6.
• 24. Quantification of cortical GABA levels in neuropsychiatric patientsSanacora G, Goddard A, Gil R, D'Souza D, Abi-Saab W, Petroff O, Mattson R, Mason G, Behar K, Ciarcia J, Berman R, Charney D, Rothman D, Krystal J. 24. Quantification of cortical GABA levels in neuropsychiatric patients. Biological Psychiatry 1998, 43: s8. DOI: 10.1016/s0006-3223(98)90472-3.
• Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humansKrystal J, Karper L, Bennett A, D’Souza D, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner J, Bowers Jr. M, Suckow R, Stetson P, Heninger G, Charney D. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998, 135: 213-229. PMID: 9498724, DOI: 10.1007/s002130050503.
• Imaging D2 Receptor Occupancy by Endogenous Dopamine in HumansLaruelle M, D’Souza C, Baldwin R, Abi-Dargham A, Kanes S, Fingado C, Seibyl J, Zoghbi S, Bowers M, Jatlow P, Charney D, Innis R. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans. Neuropsychopharmacology 1997, 17: 162-174. PMID: 9272483, DOI: 10.1016/s0893-133x(97)00043-2.
• 618 Evaluation of lorazepam blockade of M-chlorophenylpiperazine (MCPP) effects in schizophreniaZuzarte E, D’Souza D, Gil R, White J, AbiSaab D, Charney D, Krystal J. 618 Evaluation of lorazepam blockade of M-chlorophenylpiperazine (MCPP) effects in schizophrenia. Schizophrenia Research 1997, 24: 218. DOI: 10.1016/s0920-9964(97)82626-6.
• 601 Glycine ketamine interactions in healthy humansD’Souza D, Gil R, Zuzarte E, Abi-Saab D, Damon D, White J, Zimmerman L, Krystal J. 601 Glycine ketamine interactions in healthy humans. Schizophrenia Research 1997, 24: 213. DOI: 10.1016/s0920-9964(97)82609-6.
• 602 Tetrahydrocannabinol effects in schizophrenic subjects & healthy controlsD’Souza D, Gil R, Zuzarte E, Zimmerman L, Abi-Saab D, Damon D, White J, Semyak M, Krystal J. 602 Tetrahydrocannabinol effects in schizophrenic subjects & healthy controls. Schizophrenia Research 1997, 24: 213. DOI: 10.1016/s0920-9964(97)82610-2.
• 617 Dose-related ethanol effects in schizophrenic patientsZuzarte E, D’Souza D, Gil R, Genovese A, White J, Charney D, Krystal J. 617 Dose-related ethanol effects in schizophrenic patients. Schizophrenia Research 1997, 24: 218. DOI: 10.1016/s0920-9964(97)82625-4.
• 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopyBehar K, Rothman D, D’Souza D, Gil R, Petroff O, Abi-Saab D, Zuzarte E, Hooten M, Petrakis I, Sernyak M, White J, Webb E, Charnay D, Krystal J. 496 Preliminary assessment of cortical gaba levels in schizophrenics using magnetic resonance spectroscopy. Schizophrenia Research 1997, 24: 175-176. DOI: 10.1016/s0920-9964(97)82504-2.
• Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 9235-9240. PMID: 8799184, PMCID: PMC38625, DOI: 10.1073/pnas.93.17.9235.
• O-22-11 Dose response of D-Cycloserine, a partial NMDA-Glycine site agonist, in schizophreniaD’Souza D, Abi-Saab D, Damon D, White J, Gil R, Krystal J. O-22-11 Dose response of D-Cycloserine, a partial NMDA-Glycine site agonist, in schizophrenia. European Neuropsychopharmacology 1996, 6: 149. DOI: 10.1016/0924-977x(96)87994-6.
• 326. GABA-serotonin interactions in healthy subjects: Implications for psychosisGil R, D’Souza D, Zuzarte E, Damon D, Genovese A, Boutros N, Abi-Dargham A, Innis R, Charney D, Krystal J. 326. GABA-serotonin interactions in healthy subjects: Implications for psychosis. Biological Psychiatry 1996, 39: 595-596. DOI: 10.1016/0006-3223(96)84271-5.
• Dose response of oral D-cycloserine in unmedicated and medicated schizophrenicsD'Souza D, White J, Abi-Saab D, Damon D, Gil R, Zuzarte E, Krystal J. Dose response of oral D-cycloserine in unmedicated and medicated schizophrenics. Schizophrenia Research 1996, 18: 134. DOI: 10.1016/0920-9964(96)85447-8.
• SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophreniaLaruelle M, Abi-Dargham A, Gil R, van Dyck C, Erdos J, D'Souza D, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi S, Baldwin R, Hoffer P, Krystal J, Charney D, Innis R. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Research 1996, 18: 198-199. DOI: 10.1016/0920-9964(96)85619-2.
• Glycine Site Agonists of the NMDA Receptor: A ReviewD'Souza D, Charney D, Krystal J. Glycine Site Agonists of the NMDA Receptor: A Review. CNS Neuroscience & Therapeutics 1995, 1: 227-260. DOI: 10.1111/j.1527-3458.1995.tb00285.x.
• Clinical PsychopharmacologyD'Souza D. Clinical Psychopharmacology. PsycCRITIQUES 1995, 40: 680-681. DOI: 10.1037/003816.
• Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humansKrystal J, Karper L, Bennett A, Abi-Saab D, D'Souza C, Abi-Dargham A, Charney D. Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humans. Schizophrenia Research 1995, 15: 156-157. DOI: 10.1016/0920-9964(95)95485-r.
• Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamineKrystal J, Karper L, D'Souza C, Webb E, Bennett A, Abi-Dargham A, Petrakis I, Brenner L, Morrissey K, Abi-Saab D, Charney D. Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamine. Schizophrenia Research 1995, 15: 156. DOI: 10.1016/0920-9964(95)95484-q.
• Ketamine impairs learning, but not procedural expression, on the wisconsin card sorting testBennett A, Abi-Saab D, Karper L, D'Souza D, Abi-Dargham A, Charney D, Krystal J. Ketamine impairs learning, but not procedural expression, on the wisconsin card sorting test. Schizophrenia Research 1995, 15: 108-109. DOI: 10.1016/0920-9964(95)95333-5.
• Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjectsAbi-Dargham A, Krystal J, Laruelle M, D'Souza D, Zoghbi S, Brenner L, Gil R, Sernyak M, Baldwin R, Zubal G, Hoffer P, Charney D, Innis R. Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects. Schizophrenia Research 1995, 15: 75. DOI: 10.1016/0920-9964(95)95236-3.
• Intravenous glycine and oral d-Cycloserine effects on CSF Amino acids, plasma hormones and behavior in healthy humans: Implications for schizophreniaD'Souza D, Morrissey K, Abi-Saab D, Damon D, Gil R, Bennett A, Krystal J. Intravenous glycine and oral d-Cycloserine effects on CSF Amino acids, plasma hormones and behavior in healthy humans: Implications for schizophrenia. Schizophrenia Research 1995, 15: 147. DOI: 10.1016/0920-9964(95)95456-j.
• Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-D'SOUZA D, BENNETT A, ABI-DARGHAM A, KRYSTAL J. Precipitation of a Psychoneuromotor Syndrome by Fluoxetine in a Haloperidol-. Journal Of Clinical Psychopharmacology 1994, 14: 361-362. PMID: 7806697, DOI: 10.1097/00004714-199410000-00018.
• Tryptophan depletion paradigm: Implications for schizophreniaD'Souza D, Gil R, Abi-Dargham A, Karper L, Abi-Saab D, Morrissey K, Brenner L, Charney D, Krystal J. Tryptophan depletion paradigm: Implications for schizophrenia. Biological Psychiatry 1994, 35: 703. DOI: 10.1016/0006-3223(94)90974-1.
• I.V. glycine/d-cycloserine to facilitate NMDA function in humansD'Souza D, Bennett A, Karper L, Gil R, Morrissey K, Abi-Saab D, Charney D, Krystal J. I.V. glycine/d-cycloserine to facilitate NMDA function in humans. Biological Psychiatry 1994, 35: 734. DOI: 10.1016/0006-3223(94)91085-5.
• Perturbing the Organism: The Biology of Stressful ExperienceD'Souza D, Krystal J. Perturbing the Organism: The Biology of Stressful Experience. The Journal Of Nervous And Mental Disease 1994, 182: 126. DOI: 10.1097/00005053-199402000-00023.